A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)

Clinical trial NCT00989001 · TERMINATED

Trial details

NCT number: NCT00989001
Sponsor: Advanz Pharma
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Atrial Fibrillation

Start date: 2009-10-01
Primary completion: 2010-11-01
Enrollment: 217

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.